Seroquel

AstraZeneca PLC
18 May 2007



FDA Approves AstraZeneca's Once-Daily SEROQUEL XR(TM) Extended-Release Tablets 
                        For The Treatment Of Schizophrenia


AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has
approved SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets, a
once-daily medicine for the treatment of schizophrenia in adult patients. The
SEROQUEL XR development programme was based on the needs of patients and
physicians for a wider choice of medicines that offer convenient once-daily
dosing.  With SEROQUEL XR patients can achieve a dose within the recommended
range as early as the second day of treatment.

Schizophrenia is a serious brain disorder with symptoms including distorted
perceptions of reality, hallucinations and delusions, illogical thinking, and
flat or blunted emotions, affecting over two million American adults - about one
percent of the population age 18 and older.

The FDA approval was based on a clinical trial of SEROQUEL XR at doses of 400,
600, and 800 mg/day. The clinical trial was a placebo-controlled study of
inpatients and outpatients (n=573) experiencing an acute exacerbation of
symptoms of schizophrenia.  The US patent for SEROQUEL XR expires in 2017.
SEROQUEL XR will be launched in the USA in the second half of 2007.


                                     -Ends-

18 May 2007


Media Enquiries:
Edel McCaffrey, Tel: [phone]
Steve Brown, Tel: [phone]

Investor Relations:
Mina Blair, Tel: [phone]
Jonathan Hunt, Tel: [phone]

Karl Hard, Tel: [phone]
Jorgen Winroth, Tel: [phone]
Ed Seage, Tel: [phone]


                      This information is provided by RNS
            The company news service from the London Stock Exchange